Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.
Joost G E VerbeekKaren van der SluisMarieke A VolleberghJohanna W van SandickWim H van HartenValesca P RetèlPublished in: PharmacoEconomics - open (2023)
The presented early cost-effectiveness analysis suggests that adding CRS/HIPEC to systemic chemotherapy for gastric cancer patients with limited PC has a good chance of being cost-effectiveness compared with systemic chemotherapy alone when using a WTP of €80,000/QALY. However, there is substantial uncertainty in view of the current available data on effectiveness. Results from the ongoing phase III PERISCOPE II trial are therefore crucial for further decisions on treatment policy and its cost-effectiveness.
Keyphrases
- phase iii
- locally advanced
- open label
- clinical trial
- phase ii
- minimally invasive
- randomized controlled trial
- healthcare
- public health
- systematic review
- study protocol
- squamous cell carcinoma
- coronary artery bypass
- electronic health record
- rectal cancer
- radiation therapy
- big data
- machine learning
- data analysis
- artificial intelligence
- drug induced
- combination therapy
- deep learning